A breast cancer drug that reached the market on July 14 has been placed in the country's most widely used oncology treatment guidelines as a preferred option, sixteen days after approval.
Gedatolisib, sold as Revtorpyk, was added to the National Comprehensive Cancer Network breast cancer guidelines as a preferred Category 1 second-line and subsequent-line therapy, in combination with fulvestrant and with or without palbociclib, according to a July 30 announcement from its manufacturer, Celcuity.
